Promoting sustainability for seasonal malaria chemoprevention (SMC), MMV
In 2012, Seasonal Malaria Chemoprevention (SMC), a cost-effective intervention recommended by the World Health Organization, was introduced to protect children aged 3 – 59 months living in the Sahel regions of West and Central Africa, where malaria transmission is highest during and shortly after the rainy season.
To ensure that SMC remains effective and face head-on potential resistance hurdles, new drug regimens for SMC will also be needed in the coming years. Increased and sustainable financing for health, and malaria control, of which SMC is a part, is critical to protect children in the Sahel. This becomes even more pressing in the face of the risk of shifting global health priorities towards COVID-19 and other health security challenges, which jeopardizes the integrated approach to health and puts the health sector, which encompasses malaria elimination interventions, including SMC at risk.
Through the voices of the country representatives, join Medicines for Malaria Venture (MMV) to learn more and advocate for sustainable funding for SMC.
Date: Tuesday, May 18, 2021
Time: 3:00 – 4:15 pm CEST (Geneva Time)
Speakers:
- Dr. André-Marie Tchouatieu, MMV
- Dr. Peter Olumese, World Health Organization
- Suzanne Van Hulle, Catholic Relief Services
- Dr. Keziah Malm, NMCP Ghana
- Dr. Idrissa Cisse, NMCP Mali
- Dr Perpetua Uhomoibhi, NMEP Nigeria
- Hamza Djibo, Organisation Nigérienne des Educateurs Novateurs
Moderators:
- Dr. André-Marie Tchouatieu
- Suzanne Van Hulle
If you’d like to attend, please register in advance at this link.
